Drug intelligence / Profile preview

A-2

Development stage: Preclinical
Modality: Small Molecules

Overview

A-2 is a novel chemical compound synthesized as a derivative of apocynin and tandospirone. It functions as an antioxidant by decreasing reactive oxygen species (ROS) concentrations and reversing decreases in glutathione levels. Preclinical studies in rats have shown that A-2 exhibits anti-dopaminergic effects, ameliorating methamphetamine-induced hyperlocomotion in a model of schizophrenia, suggesting its potential as an antipsychotic agent.

Targets

GSH (Glutathione)

Beyond the preview

Go deeper on A-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-2.

Explore the full profile